Fujimoto T, Abe Y, Igarashi M, Ishikoh A, et al. A phase III, 52-week, open-label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis. J Dermatol 2021;48:1149-1161.
PMID: 34041788